Newsletters

FDA sleeps on AI/ML guidance. Google buys Fitbit for $2.1B

11.01.19

8 min. Read

Scoop: Stealthy OSA acquisition. Fake DTx unicorn?

10.25.19

5 min. Read

Pear-Sandoz’s conscious uncoupling. W. Virgina wants DTx.

10.18.19

7 min. Read

Roche-Genentech to develop in-house digital therapeutic. UHC. Livongo.

10.11.19

6 min. Read

Building digital therapeutics studies for the FDA vs. payers

10.04.19

15 min. Read

Senate bill mentions DTx. Pear lobbying. FDA vs payers.

10.04.19

6 min. Read

Trouble in Pear-adise? More details on ESI’s digital formulary.

9.27.19

8 min. Read

Omada hits 275K cumulative users. More on Pear, Limbix, ATX.

9.19.19

5 min. Read

Excerpts from the Pear Therapeutics Report.

9.13.19

2 min. Read

Livongo’s beyond diabetes revenue. Fitbit loses exec to CVS-Aetna

9.06.19

3 min. Read